Why is telopoietin called the "strongest weight loss drug"? ——The latest clinical trial data reveals
Share
Since its launch, Mounjaro has been widely known as the " strongest weight loss drug " for its excellent weight loss effect. Unlike traditional GLP-1 receptor agonists (such as semaglutide Wegovy ), Mounjaro is the first GLP-1 + GIP dual agonist that not only reduces appetite, but also promotes fat metabolism and improves insulin sensitivity .
The latest SURMOUNT series of clinical trials have confirmed that the weight loss effect of tebuconazole is significantly better than that of existing GLP-1 drugs , providing a more effective weight management solution for obese patients.
1. Why is tepote called the “ strongest weight loss drug ” ?
Traditional weight loss drugs (such as semaglutide) mainly rely on the action of GLP-1 , that is, reducing food intake by suppressing appetite and delaying gastric emptying , but the direct effect on fat metabolism is limited. However, telopoietin innovatively combines the dual agonist mechanism of GLP-1 + GIP , surpassing existing drugs in many aspects:
• GLP-1 effects (similar to semaglutide): reduce appetite, delay gastric emptying, and reduce glucagon secretion.
• GIP effect (unique to telportin): promotes fat decomposition, improves insulin sensitivity, and makes it easier for the body to burn stored fat.
Core advantages:
- Greater weight loss - The weight loss effect of tebuconazole is more significant than that of a single GLP-1 drug.
- Higher fat metabolism efficiency - GIP can accelerate fat burning rather than simply reduce calorie intake.
- Better long-term tolerability - compared with semaglutide, it has milder gastrointestinal side effects and is suitable for long-term use.
2. The latest clinical research data: SURMOUNT research reveals the " strongest weight loss drug "
SURMOUNT-1 study ( 2022 ) – a global Phase III clinical trial in obese or overweight patients (without diabetes) evaluating the effects of different doses of tebuconazole on weight management.
Study Design:
• The trial included 2539 patients with BMI ≥27 (overweight) or BMI ≥30 (obese) and no history of diabetes.
• The subjects were divided into four groups and received 2.5mg , 5mg , 10mg and 15mg of tirpatide injected once a week for 72 weeks.
• The main evaluation indicators were weight loss ratio and long-term safety .
Study results (after 72 weeks):
|
dose |
Average weight loss (%) |
Proportion of subjects with a weight loss of ≥20% |
|
5mg |
15.0% |
36% |
|
10mg |
19.5% |
51% |
|
15mg |
22.5% |
57% |
• The average weight loss in the 15mg tepoxetine group was 22.5% , which is the most effective FDA -approved weight loss drug .
• 57% of participants lost more than 20% of their body weight , compared with only 36% of participants taking semaglutide ( Wegovy ) in the same study ( 16.9% weight loss).
• Even in the low-dose group of 5 mg , subjects still lost an average of 15% weight , which is higher than the effect of most traditional weight loss drugs.
📌 Conclusion: Compared with semaglutide, tepoxetine can bring more significant weight loss effect in the same period of time, and at high doses, the weight loss is more than 20% .
3. Why is tepoxetine more effective than semaglutide?
( 1 ) Dual agonist mechanism: GLP-1 + GIP improves fat burning efficiency
• Semaglutide ( a GLP-1 monoagonist) acts primarily in the brain to reduce appetite, but has limited direct effects on fat metabolism.
• Tipoleptide ( GLP-1 + GIP dual agonist) additionally activates GIP receptors, improving insulin sensitivity and promoting lipolysis, allowing the body to use stored fat more efficiently.
( 2 ) Long-term use has better tolerance
• The SURMOUNT study showed that the incidence of gastrointestinal side effects (such as nausea and vomiting) of tebuconazole was lower than that of semaglutide , allowing more patients to continue taking the medication for a long time.
( 3 ) Stronger long-term weight maintenance ability
• Studies have shown that patients who used tirpotide for 72 weeks were able to maintain a lower body weight after stopping the drug . In contrast, semaglutide had a higher rebound rate after discontinuation.
4.Who is telpotide suitable for?
📌 Suitable for the crowd:
• People who want to lose significant weight (goal > 20% body weight loss).
• Users who are dissatisfied with the effects of semaglutide (weight loss less than 15% ).
• People with insulin resistance or prediabetes need to improve their metabolic health.
• People with sensitive gastrointestinal tract who wish to use GLP-1 drugs long-term .
📌 Not suitable for people:
• Patients with medullary thyroid carcinoma ( MTC ) or MEN 2 syndrome.
• Pregnant or breastfeeding women.
• Patients with severe gastrointestinal disorders such as gastroparesis.
5. Conclusion: Why is telolipidol the most powerful weight loss drug currently available?
- Stronger weight loss effect than semaglutide - after 72 weeks, the average body weight loss of the 15mg dose was 22.5% , significantly better than Wegovy ( 16.9% ).
- Unique GLP-1 + GIP mechanism - reduces appetite while promoting fat decomposition and improving insulin sensitivity.
- Better long-term tolerability - side effects are milder than traditional GLP-1 agonists and suitable for long-term use.
- Stronger ability to maintain weight - the risk of weight rebound after discontinuation is lower than that of semaglutide.
📌 In summary, tirpotide is not only the strongest weight loss drug currently approved by the FDA , but also shows superior effects in improving metabolic health and long-term weight management.